The North America Human Milk Oligosaccharides Market attained a market size of USD 133.8 million in 2025 and it is expected to reach USD 267.6 million by 2032, growing at a CAGR of 10.7% during 2026-2033.
The North America Human Milk Oligosaccharides (HMOs) Market originated from early scientific discoveries highlighting the importance of complex carbohydrates naturally present in human breast milk. Initially studied for their role in infant nutrition and immune development, HMOs gained commercial significance as advancements in glycomics, biotechnology, and microbial fermentation enabled large-scale production of key oligosaccharides such as 2’-Fucosyllactose (2’FL) and Lacto-N-neotetraose (LNnT).
The market is driven by rising awareness regarding infant nutrition, increasing adoption of premium infant formula products, growing interest in microbiome-focused healthcare, and continuous advancements in synthetic biology and fermentation technologies. Manufacturers are increasingly investing in HMO research, production capacity expansion, and innovative formulations that support digestive health, immune function, and overall wellness. Furthermore, growing regulatory acceptance and expanding clinical evidence continue to strengthen commercialization opportunities across North America.
Leading companies are focusing on biotechnology innovation, fermentation process optimization, portfolio expansion, and strategic partnerships with infant nutrition manufacturers and healthcare organizations. Investments in analytical technologies, production scalability, and regulatory compliance continue to enhance market competitiveness and support long-term growth.
Application Outlook
Based on Application, the North America Human Milk Oligosaccharides Market is segmented into Infant Formula, Dietary Supplements, Food & Beverages, and Pharmaceuticals.
The Infant Formula market dominated the North America Human Milk Oligosaccharides Market by Application in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 202.0 million by 2032, growing at a CAGR of 10.3 % during the forecast period. The Dietary Supplements market is expected to witness a CAGR of 11.2% during 2026-2033. Additionally, the Food & Beverages market is expected to witness highest CAGR of 12.1% during 2026-2033.
The Infant Formula segment garnered the highest revenue share in the market owing to increasing demand for advanced infant nutrition products that closely mimic the functional benefits of human breast milk. Dietary Supplements also recorded a significant share due to growing consumer focus on gut health, immunity, and microbiome support. Meanwhile, Food & Beverages and Pharmaceuticals continue to gain traction as manufacturers increasingly incorporate HMOs into functional nutrition products and microbiome-based therapeutic applications.
Type Outlook
Based on Type, the North America Human Milk Oligosaccharides Market is segmented into 2’FL, LNnT, 3’FL, 6’SL, 3’SL, LNT, and DFL. The 2’FL market dominated the North America Human Milk Oligosaccharides Market by Type in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 107.1 million by 2032, growing at a CAGR of 9.5 % during the forecast period. The LNnT market is expected to witness a CAGR of 9.7% during 2026-2033. Additionally, the 3’FL market is expected to witness highest CAGR of 11.3% during 2026-2033.
The 2’FL segment garnered the highest revenue share in the market owing to its extensive clinical validation, broad regulatory acceptance, and widespread use in infant nutrition products. LNnT also recorded a significant share due to increasing adoption in advanced infant formula formulations. Meanwhile, 3’FL, 6’SL, 3’SL, LNT, and DFL continue to witness growing demand as manufacturers seek to replicate the complexity and functional diversity of human breast milk.
Country Outlook
Based on Country, the North America Human Milk Oligosaccharides Market is segmented into the United States, Canada, Mexico, and Rest of North America. The US market dominated the North America Human Milk Oligosaccharides Market by country in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 194.7 million by 2032, growing at a CAGR of 10 % during the forecast period.The Canada market is expected to witness a CAGR of 12.9% during 2026-2033.
The United States acquired a major share of the market owing to strong biotechnology capabilities, extensive infant nutrition research, and increasing adoption of HMO-enriched products. Canada also recorded a significant market share supported by regulatory approvals, growing consumer awareness, and expanding investments in advanced nutrition solutions. Meanwhile, Mexico and the Rest of North America are benefiting from increasing demand for premium infant formula products, rising healthcare awareness, and growing adoption of functional nutrition ingredients.
List of Key Companies Profiled
By Application
The North America Human Milk Oligosaccharides (HMOs) Market originated from early scientific discoveries highlighting the importance of complex carbohydrates naturally present in human breast milk. Initially studied for their role in infant nutrition and immune development, HMOs gained commercial significance as advancements in glycomics, biotechnology, and microbial fermentation enabled large-scale production of key oligosaccharides such as 2’-Fucosyllactose (2’FL) and Lacto-N-neotetraose (LNnT).
The market is driven by rising awareness regarding infant nutrition, increasing adoption of premium infant formula products, growing interest in microbiome-focused healthcare, and continuous advancements in synthetic biology and fermentation technologies. Manufacturers are increasingly investing in HMO research, production capacity expansion, and innovative formulations that support digestive health, immune function, and overall wellness. Furthermore, growing regulatory acceptance and expanding clinical evidence continue to strengthen commercialization opportunities across North America.
Leading companies are focusing on biotechnology innovation, fermentation process optimization, portfolio expansion, and strategic partnerships with infant nutrition manufacturers and healthcare organizations. Investments in analytical technologies, production scalability, and regulatory compliance continue to enhance market competitiveness and support long-term growth.
Application Outlook
Based on Application, the North America Human Milk Oligosaccharides Market is segmented into Infant Formula, Dietary Supplements, Food & Beverages, and Pharmaceuticals.
The Infant Formula market dominated the North America Human Milk Oligosaccharides Market by Application in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 202.0 million by 2032, growing at a CAGR of 10.3 % during the forecast period. The Dietary Supplements market is expected to witness a CAGR of 11.2% during 2026-2033. Additionally, the Food & Beverages market is expected to witness highest CAGR of 12.1% during 2026-2033.
The Infant Formula segment garnered the highest revenue share in the market owing to increasing demand for advanced infant nutrition products that closely mimic the functional benefits of human breast milk. Dietary Supplements also recorded a significant share due to growing consumer focus on gut health, immunity, and microbiome support. Meanwhile, Food & Beverages and Pharmaceuticals continue to gain traction as manufacturers increasingly incorporate HMOs into functional nutrition products and microbiome-based therapeutic applications.
Type Outlook
Based on Type, the North America Human Milk Oligosaccharides Market is segmented into 2’FL, LNnT, 3’FL, 6’SL, 3’SL, LNT, and DFL. The 2’FL market dominated the North America Human Milk Oligosaccharides Market by Type in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 107.1 million by 2032, growing at a CAGR of 9.5 % during the forecast period. The LNnT market is expected to witness a CAGR of 9.7% during 2026-2033. Additionally, the 3’FL market is expected to witness highest CAGR of 11.3% during 2026-2033.
The 2’FL segment garnered the highest revenue share in the market owing to its extensive clinical validation, broad regulatory acceptance, and widespread use in infant nutrition products. LNnT also recorded a significant share due to increasing adoption in advanced infant formula formulations. Meanwhile, 3’FL, 6’SL, 3’SL, LNT, and DFL continue to witness growing demand as manufacturers seek to replicate the complexity and functional diversity of human breast milk.
Country Outlook
Based on Country, the North America Human Milk Oligosaccharides Market is segmented into the United States, Canada, Mexico, and Rest of North America. The US market dominated the North America Human Milk Oligosaccharides Market by country in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 194.7 million by 2032, growing at a CAGR of 10 % during the forecast period.The Canada market is expected to witness a CAGR of 12.9% during 2026-2033.
The United States acquired a major share of the market owing to strong biotechnology capabilities, extensive infant nutrition research, and increasing adoption of HMO-enriched products. Canada also recorded a significant market share supported by regulatory approvals, growing consumer awareness, and expanding investments in advanced nutrition solutions. Meanwhile, Mexico and the Rest of North America are benefiting from increasing demand for premium infant formula products, rising healthcare awareness, and growing adoption of functional nutrition ingredients.
List of Key Companies Profiled
- DSM-Firmenich AG
- International Flavors & Fragrances Inc.
- BASF SE
- Abbott Laboratories
- Nestlé S.A.
- FrieslandCampina C.V.
- Novonesis A/S
- Inbiose NV
- KYOWA HAKKO BIO Co., Ltd. (Kirin Holdings Co., Ltd.)
- ELICITYL S.A.
By Application
- Infant Formula
- Dietary Supplements
- Food & Beverages
- Pharmaceuticals
- 2’FL
- LNnT
- 3’FL
- 6’SL
- 3’SL
- LNT
- DFL
- United States
- Canada
- Mexico
- Rest of North America
Table of Contents
Chapter 1. North America Market1.1 Market Overview
1.2 Key Factors Impacting Market
1.2.1 Market Drivers
1.2.2 Market Restraints
1.2.3 Market Opportunities
1.2.4 Market Challenges
1.2.5 Market Trends
1.2.6 State of Competition
1.2.7 Market Consolidation
1.2.8 Key Customer Criteria
1.3 Product Life Cycle
1.4 Segmentation By Application
1.4.1 Infant Formula
1.4.2 Dietary Supplements
1.4.3 Food & Beverages
1.4.4 Pharmaceuticals
1.5 Segmentation By Type
1.5.1 ’FL
1.5.2 LNnT
1.5.3 ’FL
1.5.4 ’SL
1.5.5 ’SL
1.5.6 LNT
1.5.7 DFL
1.6 Segmentation By Country
1.6.1 US
1.6.1.1 Segmentation By Application
1.6.1.1.1 Infant Formula
1.6.1.1.2 Dietary Supplements
1.6.1.1.3 Food & Beverages
1.6.1.1.4 Pharmaceuticals
1.6.1.2 Segmentation By Type
1.6.1.2.1 ’FL
1.6.1.2.2 LNnT
1.6.1.2.3 ’FL
1.6.1.2.4 ’SL
1.6.1.2.5 ’SL
1.6.1.2.6 LNT
1.6.1.2.7 DFL
1.6.2 Canada
1.6.2.1 Segmentation By Application
1.6.2.1.1 Infant Formula
1.6.2.1.2 Dietary Supplements
1.6.2.1.3 Food & Beverages
1.6.2.1.4 Pharmaceuticals
1.6.2.2 Segmentation By Type
1.6.2.2.1 ’FL
1.6.2.2.2 LNnT
1.6.2.2.3 ’FL
1.6.2.2.4 ’SL
1.6.2.2.5 ’SL
1.6.2.2.6 LNT
1.6.2.2.7 DFL
1.6.3 Mexico
1.6.3.1 Segmentation By Application
1.6.3.1.1 Infant Formula
1.6.3.1.2 Dietary Supplements
1.6.3.1.3 Food & Beverages
1.6.3.1.4 Pharmaceuticals
1.6.3.2 Segmentation By Type
1.6.3.2.1 ’FL
1.6.3.2.2 LNnT
1.6.3.2.3 ’FL
1.6.3.2.4 ’SL
1.6.3.2.5 ’SL
1.6.3.2.6 LNT
1.6.3.2.7 DFL
1.6.4 Rest of North America
1.6.4.1 Segmentation By Application
1.6.4.1.1 Infant Formula
1.6.4.1.2 Dietary Supplements
1.6.4.1.3 Food & Beverages
1.6.4.1.4 Pharmaceuticals
1.6.4.2 Segmentation By Type
1.6.4.2.1 ’FL
1.6.4.2.2 LNnT
1.6.4.2.3 ’FL
1.6.4.2.4 ’SL
1.6.4.2.5 ’SL
1.6.4.2.6 LNT
1.6.4.2.7 DFL
Chapter 2. Company Snapshot
2.1 DSM-Firmenich AG
2.1.1 Business Overview
2.1.2 Key Information
2.1.3 Company Focus
2.1.4 Strategic Insights
2.1.5 Strategy Deployed
2.1.6 Product & Service Portfolio
2.1.7 Capability Overview
2.1.8 Technology & Innovation Focus
2.1.9 Customers / End Users
2.1.10 Competitive Positioning
2.1.11 Key Differentiators
2.1.12 Portfolio Matrix
2.1.13 SWOT Analysis
2.1.14 Future Outlook
2.2 Novozymes A/S
2.2.1 Business Overview
2.2.2 Key Information
2.2.3 Company Focus
2.2.4 Strategic Insights
2.2.5 Strategy Deployed
2.2.6 Product & Service Portfolio
2.2.7 Capability Overview
2.2.8 Technology & Innovation Focus
2.2.9 Customers / End Users
2.2.10 Competitive Positioning
2.2.11 Key Differentiators
2.2.12 Portfolio Matrix
2.2.13 SWOT Analysis
2.2.14 Future Outlook
2.3 International Flavors & Fragrances Inc.
2.3.1 Business Overview
2.3.2 Key Information
2.3.3 Company Focus
2.3.4 Strategic Insights
2.3.5 Strategy Deployed
2.3.6 Product & Service Portfolio
2.3.7 Capability Overview
2.3.8 Technology & Innovation Focus
2.3.9 Customers / End Users
2.3.10 Competitive Positioning
2.3.11 Key Differentiators
2.3.12 Portfolio Matrix
2.3.13 SWOT Analysis
2.3.14 Future Outlook
2.4 BASF SE
2.4.1 Business Overview
2.4.2 Key Information
2.4.3 Company Focus
2.4.4 Strategic Insights
2.4.5 Strategy Deployed
2.4.6 Product & Service Portfolio
2.4.7 Capability Overview
2.4.8 Technology & Innovation Focus
2.4.9 Customers / End Users
2.4.10 Competitive Positioning
2.4.11 Key Differentiators
2.4.12 Portfolio Matrix
2.4.13 SWOT Analysis
2.4.14 Future Outlook
2.5 Abbott Laboratories
2.5.1 Business Overview
2.5.2 Key Information
2.5.3 Company Focus
2.5.4 Strategic Insights
2.5.5 Strategy Deployed
2.5.6 Product & Service Portfolio
2.5.7 Capability Overview
2.5.8 Technology & Innovation Focus
2.5.9 Customers / End Users
2.5.10 Competitive Positioning
2.5.11 Key Differentiators
2.5.12 Portfolio Matrix
2.5.13 SWOT Analysis
2.5.14 Future Outlook
2.6 Nestlé S.A.
2.6.1 Business Overview
2.6.2 Key Information
2.6.3 Company Focus
2.6.4 Strategic Insights
2.6.5 Strategy Deployed
2.6.6 Product & Service Portfolio
2.6.7 Capability Overview
2.6.8 Technology & Innovation Focus
2.6.9 Customers / End Users
2.6.10 Competitive Positioning
2.6.11 Key Differentiators
2.6.12 Portfolio Matrix
2.6.13 SWOT Analysis
2.6.14 Future Outlook
2.7 FrieslandCampina C.V.
2.7.1 Business Overview
2.7.2 Key Information
2.7.3 Company Focus
2.7.4 Strategic Insights
2.7.5 Strategy Deployed
2.7.6 Product & Service Portfolio
2.7.7 Capability Overview
2.7.8 Technology & Innovation Focus
2.7.9 Customers / End Users
2.7.10 Competitive Positioning
2.7.11 Key Differentiators
2.7.12 Portfolio Matrix
2.7.13 SWOT Analysis
2.7.14 Future Outlook
2.8 KYOWA HAKKO BIO Co., Ltd.
2.8.1 Business Overview
2.8.2 Key Information
2.8.3 Company Focus
2.8.4 Strategic Insights
2.8.5 Strategy Deployed
2.8.6 Product & Service Portfolio
2.8.7 Capability Overview
2.8.8 Technology & Innovation Focus
2.8.9 Customers / End Users
2.8.10 Competitive Positioning
2.8.11 Key Differentiators
2.8.12 Portfolio Matrix
2.8.13 SWOT Analysis
2.8.14 Future Outlook
2.9 Inbiose NV
2.9.1 Business Overview
2.9.2 Key Information
2.9.3 Company Focus
2.9.4 Strategic Insights
2.9.5 Strategy Deployed
2.9.6 Product & Service Portfolio
2.9.7 Capability Overview
2.9.8 Technology & Innovation Focus
2.9.9 Customers / End Users
2.9.10 Competitive Positioning
2.9.11 Key Differentiators
2.9.12 Portfolio Matrix
2.9.13 SWOT Analysis
2.9.14 Future Outlook
2.10 ELICITYL S.A.
2.10.1 Business Overview
2.10.2 Key Information
2.10.3 Company Focus
2.10.4 Strategic Insights
2.10.5 Strategy Deployed
2.10.6 Product & Service Portfolio
2.10.7 Capability Overview
2.10.8 Technology & Innovation Focus
2.10.9 Customers / End Users
2.10.10 Competitive Positioning
2.10.11 Key Differentiators
2.10.12 Portfolio Matrix
2.10.13 SWOT Analysis
2.10.14 Future Outlook
Companies Mentioned
- DSM-Firmenich AG
- International Flavors & Fragrances Inc.
- BASF SE
- Abbott Laboratories
- Nestlé S.A.
- FrieslandCampina C.V.
- Novonesis A/S
- Inbiose NV
- KYOWA HAKKO BIO Co., Ltd. (Kirin Holdings Co., Ltd.)
- ELICITYL S.A.
